BRIEF-S&P says Brazil's 'BB' long-term ratings placed on Creditwatch negative on increased political uncertainty
* S&P revises brazil sovereign credit outlook to creditwatch negative from negative; current rating is BB
April 30 WellPoint Inc said on Wednesday during a conference call that it had spent $50 million on hepatitis C drugs during the first quarter.
That was the total amount the company spent in 2013 on treatments, it said. Gilead Sciences introduced Sovaldi this year, and with its $84,000 price tag and high cure rates, it has been closely watched by insurers tracking expenses.
WellPoint added $100 million in additional hepatitis C drug costs to its 2014 outlook and said it continued to watch its use closely. (Reporting by Caroline Humer; Editing by Lisa Von Ahn)
* Euro zone not ready to disburse new loans to Greece (Recasts with final news conference)
SAN FRANCISCO, May 22 The U.S. Justice Department on Monday asked a federal judge to reconsider a ruling which blocked President Donald Trump's attempt to cut off federal funding for so-called sanctuary cities.